Farallon Capital Management LLC trimmed its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 46.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 229,121 shares of the company's stock after selling 198,879 shares during the quarter. Farallon Capital Management LLC owned 0.23% of Dyne Therapeutics worth $5,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after buying an additional 978 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after buying an additional 721 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $257,000. Magnetar Financial LLC purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $263,000. Finally, E Fund Management Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after buying an additional 1,249 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 6,237 shares of company stock worth $77,760. Corporate insiders own 14.14% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on DYN. JPMorgan Chase & Co. reduced their price target on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. HC Wainwright reduced their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday. Guggenheim reaffirmed a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Scotiabank began coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $46.85.
Read Our Latest Analysis on Dyne Therapeutics
Dyne Therapeutics Price Performance
NASDAQ DYN traded up $0.14 during trading hours on Friday, hitting $11.44. The company had a trading volume of 4,515,955 shares, compared to its average volume of 1,647,259. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -3.21 and a beta of 1.19. The firm's 50 day moving average is $10.37 and its 200 day moving average is $17.98.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.
About Dyne Therapeutics
(
Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
